Skip to main content
An official website of the United States government

selective estrogen receptor degrader SRN-927

An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD SRN-927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:SERD SRN-927
Code name:SRN-927
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search